For subscribers
Wegovy is becoming too essential for its elite price
As the health benefits of anti-obesity medicines widen, pharma companies need to rethink what they charge.
Sign up now: Get ST's newsletters delivered to your inbox
Battles about the prices of innovative drugs are nothing new, but this one is on another financial scale, says the writer.
PHOTO: REUTERS
John Gapper
Follow topic:
From amphetamines to slimming pills, there is a long history of weight-loss drug crazes that ended in disappointment, or worse. Until anti-obesity medicines such as Wegovy and Zepbound, none of them had started out promisingly and then produced better and broader results.
It is surprising, but studies of the health impact of the new generation of weight drugs have steadily brought more encouraging news. One published this week found that patients who took Novo Nordisk’s Wegovy sustained weight loss for up to four years
